Therapeutic targeting of pattern-recognition receptors

被引:43
作者
Rezaei, Nima
机构
[1] Univ Tehran Med Sci, Childrens Med Ctr, Immunol Asthma & Allergy Res Inst, Tehran 14194, Iran
[2] Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England
关键词
innate immunity; NOD protein; therapeutics; Toll-like receptors;
D O I
10.1016/j.intimp.2006.02.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Innate immune system could recognize the pathogen-associated molecular patterns by pattern-recognition receptors like Toll-like receptor (TLR) and nucleotide-binding oligomerisation domain (NOD) protein. Information regarding the structure and signalling pathways of TLRs and NODs could provide opportunities for new therapeutic approaches to modulate the innate immunity. Therapeutic targeting could be done by prevention of ligand binding to leucine-rich repeats domains of receptors, blocking the interactions between receptors (like Toll/interleukin-1 receptor domains of TLRs) and adaptors in signalling pathways, blocking the enzymes in signalling pathways, and immunostimulation with vaccine adjuvants. These therapeutic approaches could be useful in the treatment of different human diseases like immunological disorders, infections, and cancers. Further research on these receptors and their signalling pathways could help scientists to identify new candidates for therapeutic targeting. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:863 / 869
页数:7
相关论文
共 58 条
[1]   The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer [J].
Adams, A ;
Navabi, H ;
Croston, D ;
Coleman, S ;
Tabi, Z ;
Clayton, A ;
Jasani, B ;
Mason, MD .
VACCINE, 2005, 23 (17-18) :2374-2378
[2]   Recognition of pathogen-associated molecular patterns by TLR family [J].
Akira, S ;
Hemmi, H .
IMMUNOLOGY LETTERS, 2003, 85 (02) :85-95
[3]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[4]   Toll-like receptors: lessons from knockout mice [J].
Akira, S .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2000, 28 :551-556
[5]   The toll-like receptor-nuclear factor κB pathway in rheumatoid arthritis [J].
Andreakos, E ;
Sacre, S ;
Foxwell, BM ;
Feldmann, M .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :2478-2488
[6]   Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents [J].
Baldridge, JR ;
McGowan, P ;
Evans, JT ;
Cluff, C ;
Mossman, S ;
Johnson, D ;
Persing, D .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1129-1138
[7]  
Barton GM, 2002, CURR TOP MICROBIOL, V270, P81
[8]   How we detect microbes and respond to them: the Toll-like receptors and their transducers [J].
Beutler, B ;
Hoebe, K ;
Du, X ;
Ulevitch, RJ .
JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 74 (04) :479-485
[9]  
Blach-Olszewska Z, 2005, ARCH IMMUNOL THER EX, V53, P245
[10]   Involvement of TLR4/type IIL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes [J].
Blanco, AM ;
Vallés, SL ;
Pascual, M ;
Guerri, C .
JOURNAL OF IMMUNOLOGY, 2005, 175 (10) :6893-6899